Immune globulin subcutaneous, human – klhw 20% solution (Xembify®, IGSC-C 20%) is effective in primary humoral immunodeficiency (PI): results from a prospective, open-label, multicenter, phase 3 study

Sleasman, John ; Lumry, William ; Hussain, Iftikhar ; Wedner, H. James ; Harris, James ; Mondou, Elsa ; Lin, Jiang ; Hames, Carrie ; Querolt, Montse ; Stein, Mark

Journal of allergy and clinical immunology, 2020-02, Vol.145 (2), p.AB71 [Periódico revisado por pares]

Texto completo disponível